Non-invasive diagnosis: Non-alcoholic fatty liver disease and alcoholic liver disease

Jose Altamirano, Qiaochu Qi, Sabina Choudhry, Mohamed Abdallah, Ashwani K. Singal, Abhinav Humar, Ramón Bataller, Amir Ali Borhani, Andrés Duarte-Rojo*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are becoming the leading causes of chronic liver disease worldwide, significantly impacting public health and healthcare cost. The development of fibrosis is the main factor leading to early mortality and morbidity in NAFLD and ALD. Thus, it is important to timely and reliably evaluate these diseases at early stages, when fibrosis is not advanced or when steatosis predominates. Liver biopsy has been the standard of reference for fibrosis and steatosis, however, its invasiveness precludes its widespread use. There is growing research on non-invasive methods for diagnosing and stratifying fibrosis and steatosis in NAFLD and ALD. This review presents clinical evidence on the use of non-invasive assessment of liver disease (blood-based and imaging-based) in patients with NALFD and ALD, and proposes algorithms incorporating these tests into their management.

Original languageEnglish (US)
Article numberA4
JournalTranslational Gastroenterology and Hepatology
StatePublished - Jan 5 2020


  • Alcoholic liver disease (ALD)
  • Fibrosis
  • Non-alcoholic fatty liver disease (NAFLD)
  • Non-invasive diagnosis
  • Steatosis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Non-invasive diagnosis: Non-alcoholic fatty liver disease and alcoholic liver disease'. Together they form a unique fingerprint.

Cite this